$TVTX
Travere Therapeutics Inc Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-K Financial Statement

#000143853319000003 Filed on February 26, 2019

Income Statement

Concept	2018 Q4	2018 Q3	2018 Q2
Revenue	$43.77M	$40.71M	$41.34M
YoY Change	104116.67%	101665.0%	6.54%
Cost Of Revenue	$1.600M	$1.133M	$1.178M
YoY Change	36.75%	22.49%	47.8%
Gross Profit	$42.17M	$39.57M	$40.16M
YoY Change	2.85%	-4571.53%	5.67%
Gross Profit Margin	96.34%	97.22%	97.15%
Selling, General & Admin	$21.54M	$26.11M	$25.10M
YoY Change	-3.84%	5.05%	-12.95%
% of Gross Profit	51.08%	65.97%	62.5%
Research & Development	$31.70M	$32.45M	$34.46M
YoY Change	62.65%	65.47%	76.88%
% of Gross Profit	75.17%	82.0%	85.81%
Depreciation & Amortization	$4.880M	$4.800M	$4.640M
YoY Change	9.42%	3.9%	4.5%
% of Gross Profit	11.57%	12.13%	11.55%
Operating Expenses	$48.76M	$76.29M	$62.90M
YoY Change	-14.99%	49.74%	20.04%
Operating Profit	-$4.985M	-$35.58M	-$21.56M
YoY Change	-67.15%	235.44%	58.55%
Interest Expense	-$2.370M	-$2.533M	-$1.057M
YoY Change	-43.97%	283.79%	60.64%
% of Operating Profit
Other Income/Expense, Net	-$2.470M	-$18.52M	-$602.0K
YoY Change	-159.68%	120.22%	-61.31%
Pretax Income	-$7.455M	-$54.10M	-$22.16M
YoY Change	-32.46%	184.49%	46.25%
Income Tax	$0.00	$415.0K	$167.0K
% Of Pretax Income
Net Earnings	-$7.455M	-$54.52M	-$22.33M
YoY Change	-57.69%	206.37%	68.79%
Net Earnings / Revenue	-17.03%	-133.93%	-54.02%
Basic Earnings Per Share	-$0.18	-$1.34	-$0.56
Diluted Earnings Per Share	-$0.18	-$1.34	-$0.56
COMMON SHARES
Basic Shares Outstanding	41.25M shares	40.43M shares	39.94M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$311.3M	$350.9M	$255.7M
YoY Change	39.83%	15.47%	-13.61%
Cash & Equivalents	$102.9M	$154.8M	$89.31M
Short-Term Investments	$208.5M	$196.1M	$166.4M
Other Short-Term Assets	$5.900M	$5.600M	$5.500M
YoY Change	-1.67%	115.38%	-8.33%
Inventory	$5.619M	$5.129M	$5.388M
Prepaid Expenses
Receivables	$12.66M	$13.45M	$12.32M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$495.7M	$503.0M	$278.9M
YoY Change	52.14%	54.6%	-12.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.146M	$3.323M	$3.455M
YoY Change	-2.6%	22.3%	36.02%
Goodwill	$936.0K	$936.0K	$936.0K
YoY Change	0.0%	0.0%	0.0%
Intangibles	$186.7M
YoY Change	1.01%
Long-Term Investments	$15.00M	$15.00M	$15.00M
YoY Change
Other Assets	$7.709M	$7.393M	$5.351M
YoY Change	38.75%	4.11%	47.49%
Total Long-Term Assets	$213.5M	$213.2M	$212.2M
YoY Change	9.74%	9.24%	13.2%
TOTAL ASSETS
Total Short-Term Assets	$495.7M	$503.0M	$278.9M
Total Long-Term Assets	$213.5M	$213.2M	$212.2M
Total Assets	$709.2M	$716.2M	$491.1M
YoY Change	36.29%	37.59%	-3.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.954M	$9.314M	$7.847M
YoY Change	-63.28%	26.38%	-13.54%
Accrued Expenses	$49.70M	$43.35M	$35.27M
YoY Change	37.97%	34.4%	27.8%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$22.50M	$22.40M	$45.40M
YoY Change
Total Short-Term Liabilities	$104.6M	$99.87M	$103.5M
YoY Change	22.12%	19.03%	29.98%
LONG-TERM LIABILITIES
Long-Term Debt	$195.1M	$192.8M	$0.00
YoY Change	332.59%	329.4%	-100.0%
Other Long-Term Liabilities	$17.55M	$4.885M	$4.880M
YoY Change	609.75%	28.28%	26.72%
Total Long-Term Liabilities	$17.55M	$4.885M	$4.880M
YoY Change	609.75%	28.28%	26.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$104.6M	$99.87M	$103.5M
Total Long-Term Liabilities	$17.55M	$4.885M	$4.880M
Total Liabilities	$390.9M	$397.1M	$203.2M
YoY Change	72.05%	83.86%	-3.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$270.0M	-$262.6M	-$208.0M
YoY Change	51.99%	64.06%	46.26%
Common Stock	$589.8M	$582.7M	$497.2M
YoY Change	25.01%	25.27%	13.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$318.3M	$319.1M	$288.0M
YoY Change
Total Liabilities & Shareholders Equity	$709.2M	$716.2M	$491.1M
YoY Change	36.29%	37.59%	-3.15%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2018 Q2
OPERATING ACTIVITIES
Net Income	-$7.455M	-$54.52M	-$22.33M
YoY Change	-57.69%	206.37%	68.79%
Depreciation, Depletion And Amortization	$4.880M	$4.800M	$4.640M
YoY Change	9.42%	3.9%	4.5%
Cash From Operating Activities	-$3.570M	-$3.900M	-$2.760M
YoY Change	315.12%	-162.9%	-150.46%
INVESTING ACTIVITIES
Capital Expenditures	-$3.860M	-$3.850M	-$3.730M
YoY Change	31.29%	2.94%	23.92%
Acquisitions
YoY Change
Other Investing Activities	-$44.94M	-$157.7M	$31.65M
YoY Change	-1682.39%	-10340.26%	-32.36%
Cash From Investing Activities	-$48.80M	-$161.6M	$27.91M
YoY Change	44263.64%	7310.55%	-36.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	520.0K	231.0M	3.080M
YoY Change	-62.04%	3861.58%	-262.11%
NET CHANGE
Cash From Operating Activities	-3.570M	-3.900M	-2.760M
Cash From Investing Activities	-48.80M	-161.6M	27.91M
Cash From Financing Activities	520.0K	231.0M	3.080M
Net Change In Cash	-51.85M	65.51M	28.23M
YoY Change	-13062.5%	565.08%	-40.35%
FREE CASH FLOW
Cash From Operating Activities	-$3.570M	-$3.900M	-$2.760M
Capital Expenditures	-$3.860M	-$3.850M	-$3.730M
Free Cash Flow	$290.0K	-$50.00K	$970.0K
YoY Change	-86.06%	-100.5%	-88.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41412835	shares
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	912685763	USD
CY2018	dei	Entity Registrant Name EntityRegistrantName	Retrophin, Inc.
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	false
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2018	dei	Trading Symbol TradingSymbol	rtrx
CY2017Q4	rtrx	Accrued Government Rebate Reserves AccruedGovernmentRebateReserves	5883000	USD
CY2018Q4	rtrx	Accrued Government Rebate Reserves AccruedGovernmentRebateReserves	8464000	USD
CY2017Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	1523000	USD
CY2018Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	4475000	USD
CY2017Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	6989000	USD
CY2018Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	16515000	USD
CY2017Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3896000	USD
CY2018Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	2990000	USD
CY2017Q4	rtrx	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	13095000	USD
CY2018Q4	rtrx	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	13049000	USD
CY2016	rtrx	Accrued Royalty In Excess Of Minimum Payable To Sellers AccruedRoyaltyInExcessOfMinimumPayableToSellers	11206000	USD
CY2017	rtrx	Accrued Royalty In Excess Of Minimum Payable To Sellers AccruedRoyaltyInExcessOfMinimumPayableToSellers	13247000	USD
CY2018	rtrx	Accrued Royalty In Excess Of Minimum Payable To Sellers AccruedRoyaltyInExcessOfMinimumPayableToSellers	14572000	USD
CY2017Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	6429000	USD
CY2018Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	6805000	USD
CY2017Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	9100000	USD
CY2018Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	19350000	USD
CY2017Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	80900000	USD
CY2018Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	73650000	USD
CY2016	rtrx	Adjustment In Connection With Legal Fee Settlement Short Swing Profit Recovery AdjustmentInConnectionWithLegalFeeSettlementShortSwingProfitRecovery	2025000	USD
CY2017	rtrx	Adjustment In Connection With Legal Fee Settlement Short Swing Profit Recovery AdjustmentInConnectionWithLegalFeeSettlementShortSwingProfitRecovery	0	USD
CY2018	rtrx	Adjustment In Connection With Legal Fee Settlement Short Swing Profit Recovery AdjustmentInConnectionWithLegalFeeSettlementShortSwingProfitRecovery	0	USD
CY2016	rtrx	Amendment To Extend Term Of Agreement AmendmentToExtendTermOfAgreement	0	USD
CY2017	rtrx	Amendment To Extend Term Of Agreement AmendmentToExtendTermOfAgreement	5885000	USD
CY2018	rtrx	Amendment To Extend Term Of Agreement AmendmentToExtendTermOfAgreement	0	USD
CY2016	rtrx	Business Combination Contingent Consideration Arrangements Changein Amountof Contingent Consideration Payment BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationPayment	4416000	USD
CY2017	rtrx	Business Combination Contingent Consideration Arrangements Changein Amountof Contingent Consideration Payment BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationPayment	3949000	USD
CY2018	rtrx	Business Combination Contingent Consideration Arrangements Changein Amountof Contingent Consideration Payment BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationPayment	8085000	USD
CY2018Q1	rtrx	Business Combination Option Agreement Contingent Consideration BusinessCombinationOptionAgreementContingentConsideration	25000000	USD
CY2018Q1	rtrx	Business Combination Option Agreement Percent Of Consideration Paid In Cash If Share Price Falls Below Share Price Threshold BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold	1
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price BusinessCombinationOptionAgreementPurchasePrice	65000000	USD
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price Percent Transfered In Cash BusinessCombinationOptionAgreementPurchasePricePercentTransferedInCash	0.2
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price Percent Transferred By Issuance Of Equity BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity	0.8
CY2018Q4	rtrx	Business Combination Option Agreement Share Price BusinessCombinationOptionAgreementSharePrice	21.40
CY2018Q1	rtrx	Business Combination Option Agreement Weighted Average Ten Day Share Price Which Requires All Cash Payment BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment	19.26
CY2016	rtrx	Change In Fair Value Of Derivative Instruments ChangeInFairValueOfDerivativeInstruments	-1655000	USD
CY2017	rtrx	Change In Fair Value Of Derivative Instruments ChangeInFairValueOfDerivativeInstruments	0	USD
CY2018	rtrx	Change In Fair Value Of Derivative Instruments ChangeInFairValueOfDerivativeInstruments	0	USD
CY2016	rtrx	Change In Fair Value Of Derivative Instruments In Shares ChangeInFairValueOfDerivativeInstrumentsInShares	0	shares
CY2017	rtrx	Change In Fair Value Of Derivative Instruments In Shares ChangeInFairValueOfDerivativeInstrumentsInShares	0	shares
CY2018	rtrx	Change In Fair Value Of Derivative Instruments In Shares ChangeInFairValueOfDerivativeInstrumentsInShares	0	shares
CY2016	rtrx	Change In Fv Of Derivative Liability Warrants ChangeInFvOfDerivativeLiabilityWarrants	-0.0110
CY2017	rtrx	Change In Fv Of Derivative Liability Warrants ChangeInFvOfDerivativeLiabilityWarrants	-0.0282
CY2018	rtrx	Change In Fv Of Derivative Liability Warrants ChangeInFvOfDerivativeLiabilityWarrants	0.0000
CY2018	rtrx	Common Stock Number Of Tranches CommonStockNumberOfTranches	5	tranche
CY2018	rtrx	Common Stock Voting Rights Number Of Votes CommonStockVotingRightsNumberOfVotes	1	vote
	rtrx	Debt Conversion Equity DebtConversionEquity	77400000	USD
CY2018Q3	rtrx	Debt Conversion Liability DebtConversionLiability	198600000	USD
CY2018Q4	rtrx	Debt Instrument Convertible Note Market Price Per1000 DebtInstrumentConvertibleNoteMarketPricePer1000	897	USD
CY2018Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	0	USD
CY2018Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	22000	USD
CY2017Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	302000	USD
CY2018Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	662000	USD
CY2017Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	424000	USD
CY2018Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	639000	USD
CY2017Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	123574000	USD
CY2017Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	78388000	USD
CY2018Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	209137000	USD
CY2018Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	160810000	USD
CY2016	rtrx	Deferred Income Tax Expense Benefit Netof Valuation Allowance DeferredIncomeTaxExpenseBenefitNetofValuationAllowance	-22661000	USD
CY2017	rtrx	Deferred Income Tax Expense Benefit Netof Valuation Allowance DeferredIncomeTaxExpenseBenefitNetofValuationAllowance	-6425000	USD
CY2018	rtrx	Deferred Income Tax Expense Benefit Netof Valuation Allowance DeferredIncomeTaxExpenseBenefitNetofValuationAllowance	0	USD
CY2017Q4	rtrx	Deferred Tax Assets Contingent Consideration DeferredTaxAssetsContingentConsideration	23080000	USD
CY2018Q4	rtrx	Deferred Tax Assets Contingent Consideration DeferredTaxAssetsContingentConsideration	23459000	USD
CY2017Q4	rtrx	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	27624000	USD
CY2018Q4	rtrx	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	36194000	USD
CY2017Q4	rtrx	Deferred Tax Liabilities Deferred Gainon Installment Sale DeferredTaxLiabilitiesDeferredGainonInstallmentSale	0	USD
CY2018Q4	rtrx	Deferred Tax Liabilities Deferred Gainon Installment Sale DeferredTaxLiabilitiesDeferredGainonInstallmentSale	18419000	USD
CY2017Q4	rtrx	Deferred Tax Liabilities Tax Basis Depreciation Lessthan Book Depreciation DeferredTaxLiabilitiesTaxBasisDepreciationLessthanBookDepreciation	0	USD
CY2018Q4	rtrx	Deferred Tax Liabilities Tax Basis Depreciation Lessthan Book Depreciation DeferredTaxLiabilitiesTaxBasisDepreciationLessthanBookDepreciation	0	USD
CY2016	rtrx	Derivative Financial Instruments Warrants Issued Recorded In Interest Expense DerivativeFinancialInstrumentsWarrantsIssuedRecordedInInterestExpense	262000	USD
CY2017	rtrx	Derivative Financial Instruments Warrants Issued Recorded In Interest Expense DerivativeFinancialInstrumentsWarrantsIssuedRecordedInInterestExpense	609000	USD
CY2018	rtrx	Derivative Financial Instruments Warrants Issued Recorded In Interest Expense DerivativeFinancialInstrumentsWarrantsIssuedRecordedInInterestExpense	2457000	USD
CY2016	rtrx	Effective Income Tax Rate Reconciliation Loss On Extinguishment Of Debt Percent EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebtPercent	0.0000
CY2017	rtrx	Effective Income Tax Rate Reconciliation Loss On Extinguishment Of Debt Percent EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebtPercent	0.0000
CY2018	rtrx	Effective Income Tax Rate Reconciliation Loss On Extinguishment Of Debt Percent EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebtPercent	0.0409
CY2016	rtrx	Effective Income Tax Rate Reconciliation Non Taxable Bargain Purchase Gain EffectiveIncomeTaxRateReconciliationNonTaxableBargainPurchaseGain	0.0000
CY2017	rtrx	Effective Income Tax Rate Reconciliation Non Taxable Bargain Purchase Gain EffectiveIncomeTaxRateReconciliationNonTaxableBargainPurchaseGain	0.0000
CY2018	rtrx	Effective Income Tax Rate Reconciliation Non Taxable Bargain Purchase Gain EffectiveIncomeTaxRateReconciliationNonTaxableBargainPurchaseGain	-0.2177
CY2016	rtrx	Exercise Of Warrants And Reclassification Of Derivative Liability ExerciseOfWarrantsAndReclassificationOfDerivativeLiability	20720000	USD
CY2017	rtrx	Exercise Of Warrants And Reclassification Of Derivative Liability ExerciseOfWarrantsAndReclassificationOfDerivativeLiability	14866000	USD
CY2018	rtrx	Exercise Of Warrants And Reclassification Of Derivative Liability ExerciseOfWarrantsAndReclassificationOfDerivativeLiability	5305000	USD
CY2016	rtrx	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	12588000	USD
CY2017	rtrx	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	596000	USD
CY2018	rtrx	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	16630000	USD
CY2016	rtrx	Increase Decrease In Settlement Expense IncreaseDecreaseInSettlementExpense	-5212000	USD
CY2017	rtrx	Increase Decrease In Settlement Expense IncreaseDecreaseInSettlementExpense	-2625000	USD
CY2018	rtrx	Increase Decrease In Settlement Expense IncreaseDecreaseInSettlementExpense	0	USD
CY2016	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	1927000	USD
CY2017	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	651000	USD
CY2018	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	0	USD
CY2016	rtrx	Legal Accrual Reversal LegalAccrualReversal	2967000	USD
CY2017	rtrx	Legal Accrual Reversal LegalAccrualReversal	0	USD
CY2018	rtrx	Legal Accrual Reversal LegalAccrualReversal	0	USD
CY2018Q4	rtrx	Number Of Products Sold NumberOfProductsSold	3	product
CY2016	rtrx	Other Federal Income Tax Expense OtherFederalIncomeTaxExpense	-0.0309
CY2017	rtrx	Other Federal Income Tax Expense OtherFederalIncomeTaxExpense	-0.0125
CY2018	rtrx	Other Federal Income Tax Expense OtherFederalIncomeTaxExpense	-0.0106
CY2016	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	2000000	USD
CY2017	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	2000000	USD
CY2018	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	2000000	USD
CY2016	rtrx	Paymentsto Security Deposits PaymentstoSecurityDeposits	0	USD
CY2017	rtrx	Paymentsto Security Deposits PaymentstoSecurityDeposits	0	USD
CY2018	rtrx	Paymentsto Security Deposits PaymentstoSecurityDeposits	15000000	USD
CY2016	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	47500000	USD
CY2017	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	47500000	USD
CY2016	rtrx	Present Value Of Contingent Consideration Payable Upon Acquisition Related To Ludca PresentValueOfContingentConsiderationPayableUponAcquisitionRelatedToLUDCA	25000000	USD
CY2017	rtrx	Present Value Of Contingent Consideration Payable Upon Acquisition Related To Ludca PresentValueOfContingentConsiderationPayableUponAcquisitionRelatedToLUDCA	0	USD
CY2018	rtrx	Present Value Of Contingent Consideration Payable Upon Acquisition Related To Ludca PresentValueOfContingentConsiderationPayableUponAcquisitionRelatedToLUDCA	0	USD
CY2018	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	0	USD
CY2016	rtrx	Reclassification Of Derivative Liability Of Warrants With Down Round Provisions ReclassificationOfDerivativeLiabilityOfWarrantsWithDownRoundProvisions	0	USD
CY2017	rtrx	Reclassification Of Derivative Liability Of Warrants With Down Round Provisions ReclassificationOfDerivativeLiabilityOfWarrantsWithDownRoundProvisions	0	USD
CY2018	rtrx	Reclassification Of Derivative Liability Of Warrants With Down Round Provisions ReclassificationOfDerivativeLiabilityOfWarrantsWithDownRoundProvisions	15710000	USD
CY2016	rtrx	Reclassification Of Derivative Liability To Equity ReclassificationOfDerivativeLiabilityToEquity	14715000	USD
CY2017	rtrx	Reclassification Of Derivative Liability To Equity ReclassificationOfDerivativeLiabilityToEquity	11221000	USD
CY2018	rtrx	Reclassification Of Derivative Liability To Equity ReclassificationOfDerivativeLiabilityToEquity	0	USD
CY2017	rtrx	Restructuring Charges Current Period RestructuringChargesCurrentPeriod	3608000	USD
CY2018	rtrx	Restructuring Charges Current Period RestructuringChargesCurrentPeriod	0	USD
CY2017	rtrx	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpense	13000000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18938000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6954000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13872000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14490000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	36018000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49695000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2000000	USD
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2100000	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7749000	USD
CY2018Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	10446000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	585000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1138000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1015000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1529000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	471800000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	589795000	USD
CY2016	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1976000	USD
CY2017	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1723000	USD
CY2018	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1357000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Income Tax Deficiency From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation	359000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29102000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26874000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19774000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	200000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1097000	USD
CY2017	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1338000	USD
CY2018	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	382000	USD
CY2016	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	656000	USD
CY2017	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	656000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3398000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	369947000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	201236000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37805000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41002000	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15993000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	17331000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18028000	USD
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9373686	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11039901	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16299349	shares
CY2017Q4	us-gaap	Assets Assets	520346000	USD
CY2018Q4	us-gaap	Assets Assets	709160000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	325807000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	495678000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	22000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	726000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1301000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	201962000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	368668000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	123272000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	208475000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	77964000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	160193000	USD
CY2016	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	18383000	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	19389000	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	11590000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99394000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102873000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3197000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	58392000	USD
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3479000	USD
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39373745	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41389524	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39373745	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41389524	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47711000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60256000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-103192000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1916000	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	930000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	5351000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	5619000	USD
CY2017Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
CY2018Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	22457000	USD
CY2017Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	45077000	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3847000	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1540000	USD
CY2018Q3	us-gaap	Debt Instrument Repurchase Amount DebtInstrumentRepurchaseAmount	23400000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6425000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	16810000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	32707000	USD
CY2018Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	195091000	USD
CY2016	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4554000	USD
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3605000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5527000	USD
CY2017Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-4868000	USD
CY2018Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	15710000	USD
CY2018Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	15700000	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	13137000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	6991000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	698000	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	12982000	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7793000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	811000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-155000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	802000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	113000	USD
CY2018	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	1.3
CY2018Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.077
CY2018Q3	us-gaap	Debt Instrument Repurchase Amount DebtInstrumentRepurchaseAmount	23400000	USD
CY2016	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	100000	USD
CY2017	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2018	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-18814000	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-7965000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2018Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	8800000	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-22661000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	44434000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	68900000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1099000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9700000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	358000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	555000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1599000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	14715000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	15695000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	16761000	USD
CY2016	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	500000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36200000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36194000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2603000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3710000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27624000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	16810000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	14288000	USD
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	600000	USD
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	900000	USD
CY2016	us-gaap	Depreciation Depreciation	100000	USD
CY2017	us-gaap	Depreciation Depreciation	500000	USD
CY2018	us-gaap	Depreciation Depreciation	600000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16135000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17804000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18668000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	15700000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	15710000	USD
CY2018Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.29
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.54
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.34
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.54
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.29
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.54
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.34
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.54
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	117000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-58000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-135000	USD
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.1835
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0245
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0093
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1630
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2162
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0979
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.2329
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0104
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0115
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0348
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0142
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0205
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0010
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0316
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0330
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.1186
CY2017Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2018Q4	us-gaap	Equity Method Investments EquityMethodInvestments	15000000	USD
CY2018Q4	us-gaap	Equity Method Investments EquityMethodInvestments	15000000	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1655000	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4491000	USD
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	51046000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	68952000	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0444
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0158
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0579
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	65707000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	19166000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	18825000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	19125000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	19158000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	19210000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	161191000	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1081000	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-464000	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	93000	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-339000	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	39000	USD
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-17042000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2016	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2016	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2017	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2018	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-57582000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13154000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15154000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19017000	USD
CY2017Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11038000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-58363000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18149000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22162000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-54101000	USD
CY2018Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7455000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-101867000	USD
CY2017Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	USD
CY2018Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	USD
CY2016	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2017	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2018	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9679000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2064000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1925000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1223000	USD
CY2017Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6580000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1368000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	229000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	167000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	415000	USD
CY2018Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	811000	USD
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	7933000	USD
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	7172000	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	218000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2916000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2060000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2708000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6090000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4945000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-152000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	568000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1706000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2773000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2447000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2702000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1358000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	-4644000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	-621000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	-1126000	USD
CY2017Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	235863000	USD
CY2018Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	255643000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	184817000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	186691000	USD
CY2016	us-gaap	Interest Expense InterestExpense	4734000	USD
CY2016	us-gaap	Interest Expense InterestExpense	4700000	USD
CY2017	us-gaap	Interest Expense InterestExpense	4422000	USD
CY2017	us-gaap	Interest Expense InterestExpense	4400000	USD
CY2018	us-gaap	Interest Expense InterestExpense	9810000	USD
CY2018	us-gaap	Interest Expense InterestExpense	9800000	USD
CY2016	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	3975000	USD
CY2017	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	3234000	USD
CY2018	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	5499000	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	2070000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	2070000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	1880000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3435000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4689000	USD
CY2017Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	700000	USD
CY2018Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1800000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	227212000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	390907000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	520346000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	709160000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	85668000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	104621000	USD
CY2016	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	5212000	USD
CY2017	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	2600000	USD
CY2017	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	2625000	USD
CY2018	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
CY2017Q4	us-gaap	Marketable Securities MarketableSecurities	201236000	USD
CY2018Q4	us-gaap	Marketable Securities MarketableSecurities	368668000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3849000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5445000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	231863000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10370000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	45602000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-203291000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3441000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7403000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24958000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-47903000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-11090000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-13229000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-17794000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-17618000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-59731000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-18378000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-22329000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-54516000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-7455000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-102678000	USD
CY2016	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-49558000	USD
CY2017	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-59731000	USD
CY2018	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-102678000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	632000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1254000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1556000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8409000	USD
CY2017Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4139000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4572000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-237000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-602000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18518000	USD
CY2018Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2470000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-21827000	USD
CY2018	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2016	us-gaap	Operating Expenses OperatingExpenses	191805000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	48028000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	52398000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	50948000	USD
CY2017Q4	us-gaap	Operating Expenses OperatingExpenses	57354000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	208728000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	56344000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	62897000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	76289000	USD
CY2018Q4	us-gaap	Operating Expenses OperatingExpenses	48756000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	244286000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-58214000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14408000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13598000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10608000	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-15177000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-53791000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17912000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-21560000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-35583000	USD
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4985000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-80040000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	14025000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2343000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	2637000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2560000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2486000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2414000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1585000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5556000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7709000	USD
CY2016	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	99000	USD
CY2017	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-186000	USD
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-553000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	99000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-186000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-553000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3902000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4065000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2472000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4496000	USD
CY2016	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-54000	USD
CY2017	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	83000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	396000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-264000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1107000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-474000	USD
CY2016	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	10511000	USD
CY2017	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	4099000	USD
CY2018	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	9721000	USD
CY2016	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
CY2017	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
CY2018	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	8820000	USD
CY2017	us-gaap	Payments For Restructuring PaymentsForRestructuring	897000	USD
CY2018	us-gaap	Payments For Restructuring PaymentsForRestructuring	3307000	USD
CY2016	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	615000	USD
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	10496000	USD
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	13122000	USD
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18974000	USD
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	184111000	USD
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	102415000	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	331345000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1428000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	887000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	727000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3112000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2312000	USD
CY2017Q4	us-gaap	Prepaid Taxes PrepaidTaxes	2842000	USD
CY2018Q4	us-gaap	Prepaid Taxes PrepaidTaxes	1716000	USD
CY2016	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	276000000	USD
CY2016	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	6005000	USD
CY2017	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3645000	USD
CY2018	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	5305000	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	91941000	USD
CY2016	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-359000	USD
CY2017	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	664000	USD
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	1714000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	159520000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	159500000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	114526000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	114500000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	162800000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-177655000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-270017000	USD
CY2016	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	133591000	USD
CY2017Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33620000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	101333000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	103654000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	29102000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	26874000	USD
CY2017	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	852000	USD
CY2018	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	1000000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70822000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	78168000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	162755000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4016000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8087000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10588000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3815000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4284000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3230000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3146000	USD
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	200000	USD
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	200000	USD
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2016	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	19774000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3793017	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4610233	shares
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	123757000	USD
CY2016	us-gaap	Restructuring Charges RestructuringCharges	893000	USD
CY2017	us-gaap	Restructuring Charges RestructuringCharges	3608000	USD
CY2018	us-gaap	Restructuring Charges RestructuringCharges	-242000	USD
CY2016Q4	us-gaap	Restructuring Reserve RestructuringReserve	893000	USD
CY2017Q4	us-gaap	Restructuring Reserve RestructuringReserve	3549000	USD
CY2018Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	USD
CY2017	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	-55000	USD
CY2018	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	-242000	USD
CY2018	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	-200000	USD
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	40203000	USD
CY2016	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	1000000	USD
CY2017Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38800000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40340000	USD
CY2017Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	42177000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	154937000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38432000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41337000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40706000	USD
CY2018Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	43771000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	164246000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4834781	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	14.94
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	15.97
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	16.81
CY2016Q4	us-gaap	Share Price SharePrice	18.93
CY2017Q4	us-gaap	Share Price SharePrice	21.07
CY2018Q4	us-gaap	Share Price SharePrice	22.63
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	23358000	USD
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	31991000	USD
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	35387000	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y9M26D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M6D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y11M23D
CY2016	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	4016000	USD
CY2017	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	8087000	USD
CY2018	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	10588000	USD
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	74945000	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	893000	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2269000	USD
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	29102000	USD
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	26645000	USD
CY2018	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	19494000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	299971000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	307767000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	293134000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	318253000	USD
CY2016	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	96000	USD
CY2017	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-339000	USD
CY2018	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	39000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1500000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1500000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12000000	USD
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8600000	USD
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38288012	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38769816	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40433171	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36997865	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38769816	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40433171	shares
CY2018	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Reclassifications</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Certain reclassifications have been made to the prior year financial statements in order to conform to the current year’s presentation.</font></div></div>
CY2018	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#07357f;font-style:normal;font-weight:bold;text-decoration:none;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Retrophin, Inc. (“we”, “our”, “us”, “Retrophin” and the “Company”) refers to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on identifying, developing and delivering life-changing therapies to people with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with serious or rare diseases and that we believe offer attractive growth characteristics. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#2c2c2c;font-style:italic;font-weight:bold;text-decoration:none;">The Company is developing the following pipeline products:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is developing fosmetpantotenate (RE-024), a novel small molecule, as a potential treatment for PKAN. PKAN is a genetic neurodegenerative disorder that is typically diagnosed in the first decade of life.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">,</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> also known as RE-021, is an investigational product candidate with a dual mechanism of action, a potent angiotensin receptor blocker (“ARB”) and selective endothelin receptor antagonist (“ERA”), with in vitro selectivity toward endothelin receptor type A. </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan is currently being evaluated in two pivotal Phase 3 clinical studies in the following indications:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;font-weight:bold;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;font-weight:bold;">Focal segmental glomerulosclerosis ("FSGS") </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">is a rare kidney disease characterized by proteinuria where the glomeruli become progressively scarred. FSGS is a leading cause of end-stage renal disease.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;font-weight:bold;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;font-weight:bold;">Immunoglobulin A nephropathy ("IgAN")</font><font style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;"> </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">is an immune-complex-mediated glomerulonephritis characterized by hematuria, proteinuria, and variable rates of progressive renal failure. IgAN is the most common primary glomerular disease.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is a party to a joint development agreement with Censa Pharmaceuticals Inc., a privately held biotechnology company focused on developing therapies for orphan metabolic diseases, to evaluate sepiapterin ("CNSA-001") for the treatment of phenylketonuria (PKU). </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In September 2017, the Company entered a three-way Cooperative Research and Development Agreement ("CRADA") with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) and patient advocacy foundation NGLY1.org to collaborate on research efforts aimed at the identification of potential small molecule therapeutics for NGLY1 deficiency.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Liquid ursodeoxycholic acid ("L-UDCA") is a liquid formulation of ursodeoxycholic acid being developed for the treatment of a rare liver disease called primary biliary cholangitis ("PBC"). The Company obtained the rights to L-UDCA in 2016 with the intention of making L-UDCA commercially available to the subset of PBC patients who have difficulty swallowing.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#2c2c2c;font-style:italic;font-weight:bold;text-decoration:none;">The Company sells the following </font><font style="font-family:Arial;font-size:10.5pt;color:#2c2c2c;font-style:italic;font-weight:bold;text-decoration:none;">three</font><font style="font-family:Arial;font-size:10.5pt;color:#2c2c2c;font-style:italic;font-weight:bold;text-decoration:none;"> products:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has been the standard of care for </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">cerebrotendinous xanthomatosis ("</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">CTX") patients for more than three decades and the Company is currently pursuing adding this indication to the label.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cholbam (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Thiola (tiopronin tablets) is approved in the United States for the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</font></div></td></tr></table></div>
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include revenue recognition, valuing equity securities in share-based payments, estimating expenses of contracted research organizations, estimating fair value of equity instruments recorded as derivative liabilities, estimating the fair value of net assets acquired in business combinations, estimating the useful lives of depreciable and amortizable assets, goodwill impairment, estimating the fair value of contingent consideration, estimating of valuation allowances and uncertain tax positions, and estimates associated with the assessment of impairment for long lived assets.</font></div></div>

Files In Submission

Name	View Source	Status
0001438533-19-000003-index-headers.html	Edgar Link	pending
0001438533-19-000003-index.html	Edgar Link	pending
0001438533-19-000003.txt	Edgar Link	pending
0001438533-19-000003-xbrl.zip	Edgar Link	pending
a5yearreturncharta04.jpg	Edgar Link	pending
ex1019-1231201810k.htm	Edgar Link	pending
ex1032-1231201810k.htm	Edgar Link	pending
ex1033-1231201810k.htm	Edgar Link	pending
ex1034-1231201810k.htm	Edgar Link	pending
ex1035-1231201810k.htm	Edgar Link	pending
ex211-1231201810k.htm	Edgar Link	pending
ex231-1231201810k.htm	Edgar Link	pending
ex311-1231201810k.htm	Edgar Link	pending
ex312-1231201810k.htm	Edgar Link	pending
ex321-1231201810k.htm	Edgar Link	pending
ex322-1231201810k.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
productpipelineq418a01.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
rtrx-20181231.xml	Edgar Link	completed
rtrx-20181231.xsd	Edgar Link	pending
rtrx-20181231x10k.htm	Edgar Link	pending
rtrx-20181231_cal.xml	Edgar Link	unprocessable
rtrx-20181231_def.xml	Edgar Link	unprocessable
rtrx-20181231_lab.xml	Edgar Link	unprocessable
rtrx-20181231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics Inc Stock $tvtx

2018 Q4 Form 10-K Financial Statement

#000143853319000003 Filed on February 26, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics Inc Stock $tvtx

2018 Q4 Form 10-K Financial Statement

#000143853319000003 Filed on February 26, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics Inc Stock $tvtx